new glp-1 receptor agonists Current Insights, Advantages and Challenges

For the dosage phenotype, we used the reported most recent weekly dosage in milligrams

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine

Novo Nordisks oral Ozempic 25 mg tablet, with a new use for T2DM, is expected in the fourth quarter of 2026

doi: 10.1016/j.tem.2025.01.002

For comparison there is a recent large retrospective cohort study (2) that uses deidentified data on patients from 66 different health care organizations

Lastly, we discuss the evidence in support of the hypothesis that the neuroprotective effects of long-term GLP-1RAs may partly be mediated by improved neurovascular coupling, and conclude with outlining some aspects as the outstanding questions